Drug Profile

UVAX 1107

Alternative Names: UVAX-1107

Latest Information Update: 13 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator The Scripps Research Institute
Developer Uvax Bio
Class AIDS vaccines; Synthetic vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I HIV-1 infections

Most Recent Events

01 Apr 2025 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV-1 infections (Prevention) in USA (IM, Injections) (NCT06905275)
21 Mar 2025 Uvax Bio completes the Phase-I clinical trials in HIV-1 infections (Prevention) in Australia (IM) (ACTRN12624000064505) (NCT06541093)
19 Nov 2024 Safety and immunogenicity data from a phase-I clinical trials in HIV-1 infections (Prevention) released by Uvax Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com